Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension
Pulmonary arterial hypertension is a progressive disease that can lead to right-sided ventricular failure and premature death. Tailoring therapy to individual patient’s needs, along with regular risk assessment, is integral for optimal outcomes in patients with pulmonary arterial hypertension. Resul...
Main Authors: | Sandeep Sahay, Franck Rahaghi |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-02-01
|
Series: | Pulmonary Circulation |
Online Access: | https://doi.org/10.1177/2045894020910098 |
Similar Items
-
Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
by: Hossein-Ardeschir Ghofrani, et al.
Published: (2020-07-01) -
Practical management of riociguat in patients with pulmonary arterial hypertension
by: Michael Halank, et al.
Published: (2019-08-01) -
Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: N. A. Tsareva, et al.
Published: (2016-12-01) -
First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension
by: Till Spreemann, et al.
Published: (2017-12-01) -
Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
by: Mizuki Momoi, et al.
Published: (2021-02-01)